Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 7Breast 2Sarcoma 1

Conditions

Sarcoma, Ewing 1

Interventions

Doxorubicin 25Cyclophosphamide 24pembrolizumab 20Specimen Handling 19Temozolomide 16Magnetic Resonance Spectroscopy 15Surgical Procedures, Operative 14Radiotherapy 13Blood Specimen Collection 13Biopsy 13atezolizumab 12Gemcitabine 12fludarabine 11Vincristine 11Ifosfamide 11X-Rays 8Trabectedin 8Nivolumab 8Irinotecan 8Imatinib Mesylate 8Drug Therapy 8cabozantinib 7Surveys and Questionnaires 7Radiation 7liposomal doxorubicin 5abemaciclib 5Sunitinib 5Standard of Care 5Radiation Dose Hypofractionation 5Dactinomycin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × naxitamab × Sarcoma × Clear all
NCT05968768 2025-04-10

To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma (Butterfly)

Institute of Mother and Child, Warsaw, Poland

Phase 2 Recruiting
24 enrolled
Sarcoma

Sarcoma, Ewing

Data powered by HemOnc (CC BY 4.0) Colophon âš¡